Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Avalo Therapeutics Inc (NASDAQ: AVTX) was $7.03 for the day, down -6.39% from the previous closing price of $7.51. In other words, the price has decreased by -$6.39 from its previous closing price. On the day, 0.11 million shares were traded. AVTX stock price reached its highest trading level at $7.36 during the session, while it also had its lowest trading level at $6.78.
Ratios:
Our analysis of AVTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 1.42. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on December 19, 2024, initiated with a Buy rating and assigned the stock a target price of $40.
Oppenheimer Upgraded its Perform to Outperform on April 16, 2024, while the target price for the stock was maintained at $35.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 13 ’24 when Almenoff June Sherie bought 500 shares for $13.00 per share. The transaction valued at 6,500 led to the insider holds 1,000 shares of the business.
Almenoff June Sherie bought 500 shares of AVTX for $6,250 on Nov 12 ’24. The Director now owns 500 shares after completing the transaction at $12.50 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AVTX now has a Market Capitalization of 73559112 and an Enterprise Value of -5497503. For the stock, the TTM Price-to-Sale (P/S) ratio is 89.71 while its Price-to-Book (P/B) ratio in mrq is 3.23. Its current Enterprise Value per Revenue stands at -6.704 whereas that against EBITDA is 0.176.
Stock Price History:
The Beta on a monthly basis for AVTX is 0.91, which has changed by 0.02328968 over the last 52 weeks, in comparison to a change of 0.23806548 over the same period for the S&P500. Over the past 52 weeks, AVTX has reached a high of $34.46, while it has fallen to a 52-week low of $3.95. The 50-Day Moving Average of the stock is -32.94%, while the 200-Day Moving Average is calculated to be -37.14%.
Shares Statistics:
AVTX traded an average of 84.23K shares per day over the past three months and 82360 shares per day over the past ten days. A total of 9.68M shares are outstanding, with a floating share count of 8.40M. Insiders hold about 19.68% of the company’s shares, while institutions hold 55.13% stake in the company. Shares short for AVTX as of 1734048000 were 22916 with a Short Ratio of 0.27, compared to 1731628800 on 9775. Therefore, it implies a Short% of Shares Outstanding of 22916 and a Short% of Float of 0.22.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
A total of 3 analysts have provided revenue estimates for AVTX’s current fiscal year. The highest revenue estimate was $249k, while the lowest revenue estimate was $200k, resulting in an average revenue estimate of $216.33k. In the same quarter a year ago, actual revenue was $1.92M
